Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...
VQ-101 is the first small molecule to demonstrate >70% activation of the lysosomal enzyme glucocerebrosidase (GCase) in GBA-Parkinson’s (GBA-PD) patients In the ongoing Phase 1b study in patients with ...
Topline results were announced from a phase 3 trial evaluating BNC210 in patients with social anxiety disorder.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback